## Lam Research Corporation Reports Financial Results for the Quarter Ended December 27, 2015

 2015 quarter").

Highlights for the December 2015 quarter were as follows:

- Shipments of $\$ 1,288$ million and revenue of $\$ 1,426$ million.
- GAAP gross margin of $43.9 \%$, GAAP operating margin of $16.8 \%$, and GAAP diluted EPS of $\$ 1.28$.
- Non-GAAP gross margin of $45.5 \%$, non-GAAP operating margin of $20.8 \%$, and non-GAAP diluted EPS of $\$ 1.57$.


## Key Financial Data for the Quarters Ended December 27, 2015 and September 27, 2015

(in thousands, except per-share data, percentages, and basis points)

| U.S. GAAP |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |

## U.S. GAAP Financial Results


 of revenue, operating expenses of $\$ 387$ million, operating margin of $21.0 \%$ of revenue, and net income of $\$ 289$ million, or $\$ 1.66$ per diluted share, for the quarter ended September 27, 2015 (the "September 2015 quarter").
Non-GAAP Financial Results


 2015 quarter.





## Balance Sheet and Cash Flow Results



 capital expenditures; and approximately $\$ 48$ million of dividends paid to stockholders during the December 2015 quarter.


 time of acceptance. The estimated future revenue from shipments to Japanese customers was approximately $\$ 109$ million as of December $27,2015$.

## Geographic Distribution

The geographic distribution of shipments and revenue during the December 2015 quarter is shown in the following table:

| Taiwan | 38 | \% | 31 | \% |
| :---: | :---: | :---: | :---: | :---: |
| Japan | 21 | \% | 22 | \% |
| China | 9 | \% | 17 | \% |
| Korea | 15 | \% | 15 | \% |
| United States | 8 | \% | 7 | \% |
| Southeast Asia | 5 | \% | 5 | \% |
| Europe | 4 | \% | 3 | \% |

Outlook
For the March 2016 quarter, Lam is providing the following guidance:

|  | U.S. GAAP |  |  | Reconciling Items | Non-GAAP |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Shipments | \$1.43 <br> Billion | +/- | \$75 Million | - | \$1.43 <br> Billion | +/- | \$75 Million |
| Revenue | $\$ 1.30$ <br> Billion | +/- | \$75 Million | - | $\begin{aligned} & \$ 1.30 \\ & \text { Billion } \end{aligned}$ | +/- | \$75 Million |
| Gross margin | 42.4\% | +/- | 1\% | \$21 Million | 44.0\% | +/- | 1\% |
| Operating margin | 14.2\% | +/- | 1\% | \$37 Million | 17.0\% | +/- | 1\% |
| Net income per diluted share | \$0.77 | +/- | \$0.10 | \$50 Million | \$1.07 | +/- | \$0.10 |
| Diluted share count | 174.5 M |  |  | 2 Million | 172.5 M |  |  |



 the date of this release. Actual results will vary from this model and the variations may be material. Reconciling items included above are as follows:

- Gross Margin -- amortization related to intangible assets acquired in the Novellus transaction, $\$ 21$ million.
- Operating margin -- amortization related to intangible assets acquired in the Novellus transaction, $\$ 37$ million.
- Earnings per share -- amortization related to intangible assets acquired in the Novellus transaction, $\$ 37$ million; amortization of note discounts, $\$ 9$ million; amortization of bridge loan issuance costs associated with the KLA-Tencor acquisition, $\$ 18$ million and associated tax benefit for non-GAAP items ( $\$ 14$ ) million; totaling $\$ 50$ million.
- Diluted share count -- impact of a note hedge issued contemporaneously with the convertible notes due 2016 and 2018, 2 million shares.


## Use of Non-GAAP Financial Results

In addition to U.S. GAAP results, this press release also contains non-GAAP financial results. The Company's non-GAAP results for both the December 2015 and September

 issuance costs associated with the KLA-Tencor acquisition, and income tax benefit from tax extenders primarily the research and development credit; and the September issuance costs associated with the KLA-Tencor acquisition, and income tax benefit from tax ext
2015 quarter non-GAAP results exclude cumulative income tax benefits due to a court ruling.


 results are included at the end of this press release and on the Company's website at http://investor.lamresearch.com.

Cautionary Statement Regarding Forward-Looking Statements












 constitute a forecast, projection or estimate of the future financial performance of Lam, KLA-Tencor, or the merged company, following the implementation of the proposed
 metrics of Lam Research or the merged company for the current or future financial years would necessarily match or exceed the historical published figures.

## Additional Information and Where to Find It












 tencor.com) or by writing to KLA-Tencor Corporation, Investor Relations, One Technology Drive, Milpitas, California 95035 (for documents filed with the SEC by KLA-Tencor).

Participants in the Solicitation
 be participants in the solicitation of proxies from Lam and KLA-Tencor stockholders in connection with the proposed transaction. Information regarding the persons who,
 definitive joint proxy statement/prospectus that was filed with the SEC on January 13, 2016.

About Lam Research



 whose common stock trades on the Nasdaq Global Select Market(SM) under the symbol LRCX. For more information, please visit http://www.lamresearch.com. (LRCX-F)

Consolidated Financial Tables Follow.

## LAM RESEARCH CORPORATION

## CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data and percentages)

|  | Three Months Ended |  |  |  |  |  |  |  | Six Months Ended |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | December 27, |  | September 27, |  |  | December 28, |  |  | December 27, |  |  |
|  | 2015 |  | 20 |  |  |  |  |  |  |  |  |
| (unaudited) |  |  |  |  |  |  |  |  |  |  |  |
| Revenue | \$ 1,425,534 |  | \$ | 1,600,043 |  | \$ | 1,232,241 |  | \$ | 3,025,577 |  |
| Cost of goods sold | 799,024 |  | 877,680 |  |  | 695,584 |  |  | 1,676,704 |  |  |
| Gross margin | 626,510 |  | 722,363 |  |  | 536,657 |  |  | 1,348,873 |  |  |
| Gross margin as a percent of revenue | 43.9 | \% |  | 45.1 | \% |  | 43.6 | \% |  | 44.6 | \% |
| Research and development | 220,754 |  | 234,209 |  |  | 196,768 |  |  | 454,963 |  |  |
| Selling, general and administrative | 166,922 |  | 152,726 |  |  | 151,148 |  |  | 319,648 |  |  |
| Total operating expenses | 387,676 |  | 386,935 |  |  | 347,916 |  |  | 774,611 |  |  |
| Operating income | 238,834 |  | 335,428 |  |  | 188,741 |  |  | 574,262 |  |  |
| Operating <br> income <br> as a <br> percent <br> of <br> revenue | 16.8 | \% | 21.0 |  | \% | 15.3 |  | \% | 19.0 |  | \% |
| Other expense, net | (29,935 | ) |  | (27,121 | ) |  | (9,799 | ) |  | (57,056 | ) |
| Income before income taxes | 208,899 |  | 308,307 |  |  | 178,942 |  |  | 517,206 |  |  |
| Income tax benefit (expense) | 14,081 |  | (19,628 |  | ) | (2,002 |  | ) | (5,547 |  | ) |
| Net income | \$ 222,980 |  | \$ | 288,679 |  | \$ | 176,940 |  | \$ | 511,659 |  |

Net income per share:

| Basic | $\$$ | 1.41 | $\$$ | 1.82 | $\$$ | 1.11 | $\$ .23$ |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Diluted | $\$$ | 1.28 | $\$$ | 1.66 | $\$$ | 1.00 | $\$ .94$ |

## Number of shares used <br> in per share

calculations:

| Basic | 158,424 | 158,352 | 159,248 | 158,388 |
| :---: | :---: | :---: | :---: | :---: |
| Diluted | 174,242 | 174,374 | 177,046 | 174,308 |


| Cash dividend declared <br> per share | $\$$ | 0.30 | $\$$ | 0.30 | $\$$ | 0.18 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |

## LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

|  | December 27, | September 27, | June 28, |
| :--- | :--- | :--- | :--- |
| 2015 | 2015 | (1) |  |

ASSETS

| Cash and cash equivalents | \$ | 1,967,873 | \$ | 1,744,325 | \$ | 1,501,539 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Investments |  | 2,507,607 |  | 2,587,474 |  | 2,574,947 |
| Accounts receivable, net |  | 1,089,850 |  | 1,088,942 |  | 1,093,582 |
| Inventories |  | 879,821 |  | 916,683 |  | 943,346 |
| Other current assets |  | 225,046 |  | 178,557 |  | 157,435 |
| Total current assets |  | 6,670,197 |  | 6,515,981 |  | 6,270,849 |
| Property and equipment, net |  | 643,746 |  | 636,769 |  | 621,418 |
| Restricted cash and investments |  | 207,568 |  | 183,455 |  | 170,969 |
| Goodwill and intangible assets |  | 2,039,213 |  | 2,076,164 |  | 2,115,649 |
| Other assets |  | 189,697 |  | 182,062 |  | 185,763 |
| Total assets | \$ | 9,750,421 | \$ | 9,594,431 | \$ | 9,364,648 |
| LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |  |  |  |  |
| Current portion of convertible notes and capital leases | \$ | 973,697 | \$ | 969,392 | \$ | 1,359,650 |
| Other current liabilities |  | 1,249,283 |  | 1,312,549 |  | 1,271,711 |
| Total current liabilities |  | 2,222,980 |  | 2,281,941 |  | 2,631,361 |
| Long-term debt and capital leases |  | 1,404,683 |  | 1,400,615 |  | 1,001,382 |
| Income taxes payable |  | 257,502 |  | 247,448 |  | 202,930 |
| Other long-term liabilities |  | 135,303 |  | 127,607 |  | 184,023 |
| Total liabilities |  | 4,020,468 |  | 4,057,611 |  | 4,019,696 |
| Temporary equity, convertible notes |  | 177,662 |  | 178,665 |  | 241,808 |
| Stockholders' equity ${ }^{(2)}$ |  | 5,552,291 |  | 5,358,155 |  | 5,103,144 |
| Total liabilities and stockholders' equity | \$ | 9,750,421 | \$ | 9,594,431 | \$ | 9,364,648 |

(1) Derived from audited financial statements
(2) Common shares issued and outstanding were 158,568 as of December 27, 2015, 158,101 as of September 27, 2015, and 158,531 as of June 28, 2015

## LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

```
(in thousands)
```

Three Months Ended
(unaudited)

| CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net income | \$ | 222,980 |  | \$ | 288,679 |  | \$ | 176,940 |  | \$ | 511,659 |  | \$ | 3 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Depreciation and amortization |  | 71,798 |  |  | 70,590 |  |  | 69,536 |  |  | 142,388 |  |  | 1 |
| Deferred income taxes |  | 8,176 |  |  | (5,563 | ) |  | 3,320 |  |  | 2,613 |  |  | 6 |
| Equity-based compensation expense |  | 32,570 |  |  | 35,774 |  |  | 30,632 |  |  | 68,344 |  |  | 6 |
| Income tax benefit on equity-based compensation plans |  | 2,168 |  |  | 3,545 |  |  | 1,141 |  |  | 5,713 |  |  | 1 |
| Excess tax benefit on equity-based compensation plans |  | (2,181 | ) |  | (3,572 | ) |  | (599 | ) |  | (5,753 | ) |  | ( |
| Amortization of note discounts and issuance costs |  | 23,649 |  |  | 9,831 |  |  | 9,199 |  |  | 33,480 |  |  | 1 |
| Gain on sale of business |  | - |  |  | - |  |  | - |  |  | - |  |  | ( |
| Other, net |  | 10,592 |  |  | 10,011 |  |  | 1,607 |  |  | 20,603 |  |  | 7 |
| Changes in operating assets and liabilities |  | (75,207 | ) |  | 39,702 |  |  | (130,537 | ) |  | (35,505 | ) |  | (: |
| Net cash provided by operating activities |  | 294,545 |  |  | 448,997 |  |  | 161,239 |  |  | 743,542 |  |  | 3 |
| CASH FLOWS <br> FROM <br> INVESTING <br> ACTIVITIES: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Capital expenditures and intangible assets |  | (28,143 | ) |  | (49,454 | ) |  | (61,363 | ) |  | (77,597 | ) |  | ( |
| Business acquisitions, net of cash acquired |  | - |  |  | - |  |  | - |  |  | - |  |  |  |
| Net sale (purchase) of available-forsale securities |  | 39,202 |  |  | (28,203 | ) |  | (321,590 | ) |  | 10,999 |  |  | ( |
| Repayment of notes receivable |  | 8,082 |  |  | - |  |  | 3,978 |  |  | 8,082 |  |  | 3 |
| Proceeds from sale of business |  | - |  |  | - |  |  | - |  |  | - |  |  | 4 |
| Other, net |  | (4,746 | ) |  | (1,500 | ) |  | 100 |  |  | (6,246 | ) |  | 1 |
| Net cash provided by (used for) investing activities |  | 14,395 |  |  | (79,157 | ) |  | (378,875 | ) |  | (64,762 | ) |  | ( |


| CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Principal payments on long-term debt and capital lease obligations and payments for debt issuance costs |  | (28,374 | ) |  | (96 | ) |  | (674 | ) |  | (28,470 | ) |  |  |
| Excess tax benefit on equity-based compensation plans |  | 2,181 |  |  | 3,572 |  |  | 599 |  |  | 5,753 |  |  |  |
| Treasury stock purchases |  | (12,798 | ) |  | (98,385 | ) |  | (65,536 | ) |  | (111,183 | ) |  | (: |
| Dividends paid |  | (47,896 | ) |  | (47,659 | ) |  | (29,381 | ) |  | (95,555 | ) |  | (! |
| Re-issuance of treasury stock related to employee stock purchase plan |  | - |  |  | 19,245 |  |  | - |  |  | 19,245 |  |  |  |
| Proceeds from issuance of common stock |  | 1,173 |  |  | 377 |  |  | 4,223 |  |  | 1,550 |  |  | 8 |
| Other, net |  | (22 | ) |  | (300 | ) |  | - |  |  | (322 | ) |  |  |
| Net cash used for financing activities |  | (85,736 | ) |  | (123,246 | ) |  | (90,769 | ) |  | (208,982 | ) |  |  |
| Effect of exchange rate changes on cash and cash equivalents |  | 344 |  |  | (3,808 | ) |  | (3,998 | ) |  | (3,464 | ) |  |  |
| Net increase (decrease) in cash and cash equivalents |  | 223,548 |  |  | 242,786 |  |  | (312,403 | ) |  | 466,334 |  |  |  |
| Cash and cash equivalents at beginning of period |  | 1,744,325 |  |  | 1,501,539 |  |  | 1,293,678 |  |  | 1,501,539 |  |  |  |
| Cash and cash equivalents at end of period | \$ | 1,967,873 |  | \$ | 1,744,325 |  | \$ | 981,275 |  | \$ | 1,967,873 |  | \$ | 9 |

## Non-GAAP Financial Summary

(in thousands, except percentages and per share data)

```
(unaudited)
```

|  | Three Months Ended |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | December 27, |  |  | September 27, |  |  |
|  | 2015 |  |  | 2015 |  |  |
| Revenue | \$ | 1,425,534 |  | \$ | 1,600,043 |  |
| Gross margin | \$ | 648,409 |  | \$ | 743,984 |  |
| Gross margin as percentage of revenue |  | 45.5 | \% |  | 46.5 | \% |
| Operating expenses | \$ | 352,135 |  | \$ | 363,596 |  |
| Operating income | \$ | 296,274 |  | \$ | 380,388 |  |
| Operating margin as a percentage of revenue |  | 20.8 | \% |  | 23.8 | \% |


| Net income | $\$$ | 270,313 |
| :--- | :--- | :--- |
| Net income per diluted share | $\$$ | 1.57 |
| Shares used in per share calculation - diluted |  | 171,796 |

Reconciliation of U.S. GAAP Net Income to Non-GAAP Net Income and U.S. GAAP number of dilutive shares to Non-GAAP number of dilutive shares
(in thousands, except per share data)
(unaudited)

| Three Months Ended |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | December 27, |  | September 27, |  | June 28, | March 29, |
|  | 20 |  |  |  | 2015 | 2015 |
| U.S. GAAP net income | \$ | 222,980 | \$ | 288,679 | 131,271 | 206,285 |
| Pre-tax non-GAAP items: |  |  |  |  |  |  |
| Amortization related to intangible assets acquired in Novellus transaction - cost of goods sold |  | 21,250 |  | 21,250 | 21,286 | 21,286 |
| Acquisition-related inventory fair value impact - cost of goods sold |  | 649 |  | - | 1,192 | 308 |


| Impairment of long lived <br> asset - cost of goods sold | - | - | 9,821 |
| :--- | :--- | :--- | :--- |
| Restructuring charges - <br> cost of goods sold | - | 371 | - |

Restructuring charges -
research and 34 4,206
development

17,392

| Acquisition costs - |  |
| :--- | :--- |
| selling, general and | 17,392 |

administrative

6,0
16,083
16,083
intangible assets
acquired in Novellus
transaction - selling,
16,083
general and
administrative

| Restructuring charges - <br> selling, general and <br> administrative | 2,032 | 3,050 |
| :--- | :--- | :--- |


| Goodwill impairment selling, general and administrative | - |  | - |  | 79,444 |  | - |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Amortization of note discounts - other expense, net | 9,258 |  | 9,122 |  | 9,019 |  | 8,749 |  |
| Amortization of bridge Ioan issuance costs other expense, net | 13,573 |  | - |  | - |  | - |  |
| Net income tax benefit on non-GAAP items | (19,335 | ) | (7,791 | ) | (9,605 | ) | (7,181 | ) |
| Cumulative income tax benefit due to a court ruling | - |  | (21,925 | ) | - |  | - |  |

Income tax expense
(benefit) on resolution or
additional accrual for
1,078
(124
)
additional accrual for

Income tax benefit from
tax extenders, primarily
the research and
development credit
(13,603 )

| Non-GAAP net income | \$ | 270,313 |  | \$ | 313,045 |  | \$ | 260,023 |  | \$ | 244,911 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Non-GAAP net income per diluted share | \$ | 1.57 |  | \$ | 1.82 |  | \$ | 1.50 |  | \$ | 1.40 |  |
| U.S. GAAP number of shares used for per diluted share calculation |  | 174,242 |  |  | 174,374 |  |  | 176,575 |  |  | 177,531 |  |
| Effect of convertible note hedge |  | (2,446 | ) |  | (2,328 | ) |  | (2,934 | ) |  | (3,060 | ) |
| Non-GAAP number of shares used for per diluted share calculation |  | 171,796 |  |  | 172,046 |  |  | 173,641 |  |  | 174,471 |  |

Reconciliation of U.S. GAAP Gross Margin, Operating Expenses and Operating Income to Non-GAAP Gross Margin, Operating Expenses and Operating Income
(unaudited)

|  | Three Months Ended |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | December 27, |  |  | September 27, |  |  |
|  | 2015 |  |  | 2015 |  |  |
| U.S. GAAP gross margin | \$ | 626,510 |  | \$ | 722,363 |  |
| Pre-tax non-GAAP items: |  |  |  |  |  |  |
| Amortization related to intangible assets acquired in Novellus transaction - cost of goods sold |  | 21,250 |  |  | 21,250 |  |
| Acquisition-related inventory fair value impact - cost of goods sold |  | 649 |  |  | - |  |
| Restructuring charges - cost of goods sold |  | - |  |  | 371 |  |
| Non-GAAP gross margin | \$ | 648,409 |  | \$ | 743,984 |  |
| U.S. GAAP gross margin as a percentage of revenue |  | 43.9 | \% |  | 45.1 | \% |
| Non-GAAP gross margin as a percentage of revenue |  | 45.5 | \% |  | 46.5 | \% |
| U.S. GAAP operating expenses | \$ | 387,676 |  | \$ | 386,935 |  |
| Pre-tax non-GAAP items: |  |  |  |  |  |  |
| Restructuring charges - research and development |  | $(34$ | ) |  | (4,206 | ) |
| Acquisition costs - selling, general and administrative |  | (17,392 | ) |  | - |  |
| Amortization related to intangible assets acquired in Novellus transaction - selling, general and administrative |  | (16,083 | ) |  | (16,083 | ) |
| Restructuring charges - selling, general and administrative |  | (2,032 | ) |  | (3,050 | ) |
| Non-GAAP operating expenses | \$ | 352,135 |  | \$ | 363,596 |  |
| Non-GAAP operating income | \$ | 296,274 |  | \$ | 380,388 |  |
| GAAP operating margin as percent of revenue |  | 16.8 | \% |  | 21.0 | \% |
| Non-GAAP operating margin as a percent of revenue |  | 20.8 | \% |  | 23.8 | \% |

Lam Research Corporation Contacts:
Satya Kumar
Investor Relations
phone: 510-572-3232
e-mail: satya.kumar@lamresearch.com
Source: Lam Research Corporation

News Provided by Acquire MediaFREMONT, CA -- (Marketwired) -- 01/27/16 -- Lam Research Corp.(NASDAQ: LRCX) today announced financial results for the quarter ended December 27, 2015 (the "December 2015 quarter").

Highlights for the December 2015 quarter were as follows:

- Shipments of $\$ 1,288$ million and revenue of $\$ 1,426$ million.
- GAAP gross margin of $43.9 \%$, GAAP operating margin of $16.8 \%$, and GAAP diluted EPS of $\$ 1.28$.
- Non-GAAP gross margin of $45.5 \%$, non-GAAP operating margin of $20.8 \%$, and non-GAAP diluted EPS of $\$ 1.57$.

Key Financial Data for the Quarters Ended December 27, 2015 and September 27, 2015
(in thousands, except per-share data, percentages, and basis points)

| U.S. GAAP |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |

## U.S. GAAP Financial Results

For the December 2015 quarter, revenue was $\$ 1,426$ million, gross margin was $\$ 627$ million, or $43.9 \%$ of revenue, operating expenses were $\$ 388$ million, operating margin was $16.8 \%$ of revenue, and net income was $\$ 223$ million, or $\$ 1.28$ per diluted share on GAAP basis. This compares to revenue of $\$ 1,600$ million, gross margin of $\$ 722$ million, or $45.1 \%$ of revenue, operating expenses of $\$ 387$ million, operating margin of $21.0 \%$ of revenue, and net income of $\$ 289$ million, or $\$ 1.66$ per diluted share, for the quarter ended September 27, 2015 (the "September 2015 quarter").

## Non-GAAP Financial Results

For the December 2015 quarter, non-GAAP gross margin was $\$ 648$ million or $45.5 \%$ of revenue, non-GAAP operating expenses were $\$ 352$ million, non-GAAP operating margin was $20.8 \%$ of revenue, and non-GAAP net income was $\$ 270$ million, or $\$ 1.57$ per diluted share. This compares to non-GAAP gross margin of $\$ 744$ million or $46.5 \%$ of revenue, non-GAAP operating expenses of $\$ 364$ million, non-GAAP operating margin of $23.8 \%$ of revenue, and non-GAAP net income of $\$ 313$ million, or $\$ 1.82$ per diluted share for the September 2015 quarter.
"Lam's strong December quarter concludes a historic year for Lam, headlined by the delivery of nearly $\$ 6$ billion in shipments and revenue, and over six dollars in EPS," said Martin Anstice, Lam Research's president and chief executive officer. "Strong execution combined with our ability to capitalize on the inflection-driven market expansion continued to drive outperformance in profitable growth. We remain committed to invest proactively and broadly to create enabling value for our customers and growth for Lam. We are excited about our proposed business combination with KLA-Tencor, which upon completion will deliver a new and unmatched capability to the benefit of the global semiconductor industry."

## Balance Sheet and Cash Flow Results

Cash and cash equivalents, short-term investments, and restricted cash and investments balances increased to $\$ 4.7$ billion at the end of the December 2015 quarter compared to $\$ 4.5$ billion at the end of the September 2015 quarter. This increase was primarily the result of approximately $\$ 295$ million in cash flows from operating activities which was partially offset by approximately $\$ 13$ million of treasury stock repurchases related to net share settlement on employee stock-based compensation; approximately $\$ 28$ million of capital expenditures; and approximately $\$ 48$ million of dividends paid to stockholders during the December 2015 quarter.

Deferred revenue at the end of the December 2015 quarter decreased to $\$ 395$ million as compared to $\$ 517$ million at the end of the September 2015 quarter. Deferred profit at the end of the December 2015 quarter decreased to $\$ 261$ million as compared to $\$ 325$ million at the end of the September 2015 quarter. Lam's deferred revenue balance does not include shipments to Japanese customers, to whom title does not transfer until customer acceptance. Shipments to Japanese customers are classified as inventory at cost until the time of acceptance. The estimated future revenue from shipments to Japanese customers was approximately $\$ 109$ million as of December 27, 2015.
Geographic Distribution
The geographic distribution of shipments and revenue during the December 2015 quarter is shown in the following table:

| Region | Shipments |  | Revenue |  |
| :---: | :---: | :---: | :---: | :---: |
| Taiwan | 38 | \% | 31 | \% |
| Japan | 21 | \% | 22 | \% |
| China | 9 | \% | 17 | \% |
| Korea | 15 | \% | 15 | \% |
| United States | 8 | \% | 7 | \% |
| Southeast Asia | 5 | \% | 5 | \% |
| Europe | 4 | \% | 3 | \% |

## Outlook

For the March 2016 quarter, Lam is providing the following guidance:

|  | U.S. GAAP |  |  | Reconciling Items | Non-GAAP |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Shipments | $\begin{aligned} & \$ 1.43 \\ & \text { Billion } \end{aligned}$ | +/- | \$75 Million | - | $\begin{aligned} & \$ 1.43 \\ & \text { Billion } \end{aligned}$ | +/- | \$75 Million |
| Revenue | $\begin{aligned} & \$ 1.30 \\ & \text { Billion } \end{aligned}$ | +/- | \$75 Million | - | $\begin{aligned} & \text { \$1.30 } \\ & \text { Billion } \end{aligned}$ | +/- | \$75 Million |
| Gross margin | 42.4\% | +/- | 1\% | \$21 Million | 44.0\% | +/- | 1\% |
| Operating margin | 14.2\% | +/- | 1\% | \$37 Million | 17.0\% | +/- | 1\% |
| Net income per diluted share | \$0.77 | +/- | \$0.10 | \$50 Million | \$1.07 | +/- | \$0.10 |
| Diluted share count | 174.5 Million |  |  | 2 Million | 172.5 Million |  |  |



 the date of this release. Actual results will vary from this model and the variations may be material. Reconciling items included above are as follows:

- Gross Margin -- amortization related to intangible assets acquired in the Novellus transaction, $\$ 21$ million.
- Operating margin -- amortization related to intangible assets acquired in the Novellus transaction, \$37 million.
 amortization of bridge loan issuance costs associated with the KLA-Tencor acquisition, \$18 million and associated tax benefit for non-GAAP items (\$14) million; totaling $\$ 50$ million.
- Diluted share count -- impact of a note hedge issued contemporaneously with the convertible notes due 2016 and 2018,2 million shares.


## Use of Non-GAAP Financial Results

In addition to U.S. GAAP results, this press release also contains non-GAAP financial results. The Company's non-GAAP results for both the December 2015 and September

 issuance costs associated with the KLA-Tencor acquisition, and income tax benefit from tax extenders primarily the research and development credit; and the September 2015 quarter non-GAAP results exclude cumulative income tax benefits due to a court ruling.


 results are included at the end of this press release and on the Company's website at http://investor.lamresearch.com.

## Cautionary Statement Regarding Forward-Looking Statements













 constitute a forecast, projection or estimate of the future financial performance of Lam, KLA-Tencor, or the merged company, following the implementation of the proposed
 metrics of Lam Research or the merged company for the current or future financial years would necessarily match or exceed the historical published figures

## Additional Information and Where to Find It








 when they become available because they contain, or will contain, important information about the proposed transaction. You may obtain copies of all documents filed with


 tencor.com) or by writing to KLA-Tencor Corporation, Investor Relations, One Technology Drive, Milpitas, California 95035 (for documents filed with the SEC by KLA-Tencor).

## Participants in the Solicitation

 be participants in the solicitation of proxies from Lam and KLA-Tencor stockholders in connection with the proposed transaction. Information regarding the persons who,
 definitive joint proxy statement/prospectus that was filed with the SEC on January 13, 2016.

## About Lam Research




 whose common stock trades on the Nasdaq Global Select Market(SM) under the symbol LRCX. For more information, please visit http://www.lamresearch.com. (LRCX-F)

Consolidated Financial Tables Follow.

## LAM RESEARCH CORPORATION

(in thousands, except per share data and percentages)

|  | Three Months Ended |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |

## LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

## ASSETS

| Cash and cash equivalents | \$ | 1,967,873 | \$ | 1,744,325 | \$ | 1,501,539 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Investments |  | 2,507,607 |  | 2,587,474 |  | 2,574,947 |
| Accounts receivable, net |  | 1,089,850 |  | 1,088,942 |  | 1,093,582 |
| Inventories |  | 879,821 |  | 916,683 |  | 943,346 |
| Other current assets |  | 225,046 |  | 178,557 |  | 157,435 |
| Total current assets |  | 6,670,197 |  | 6,515,981 |  | 6,270,849 |
| Property and equipment, net |  | 643,746 |  | 636,769 |  | 621,418 |
| Restricted cash and investments |  | 207,568 |  | 183,455 |  | 170,969 |
| Goodwill and intangible assets |  | 2,039,213 |  | 2,076,164 |  | 2,115,649 |
| Other assets |  | 189,697 |  | 182,062 |  | 185,763 |
| Total assets | \$ | 9,750,421 | \$ | 9,594,431 | \$ | 9,364,648 |

LIABILITIES AND STOCKHOLDERS' EQUITY

| Current portion of convertible notes and capital leases | \$ | 973,697 | \$ | 969,392 | \$ | 1,359,650 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Other current liabilities |  | 1,249,283 |  | 1,312,549 |  | 1,271,711 |
| Total current liabilities |  | 2,222,980 |  | 2,281,941 |  | 2,631,361 |
| Long-term debt and capital leases |  | 1,404,683 |  | 1,400,615 |  | 1,001,382 |
| Income taxes payable |  | 257,502 |  | 247,448 |  | 202,930 |
| Other long-term liabilities |  | 135,303 |  | 127,607 |  | 184,023 |
| Total liabilities |  | 4,020,468 |  | 4,057,611 |  | 4,019,696 |
| Temporary equity, convertible notes |  | 177,662 |  | 178,665 |  | 241,808 |
| Stockholders' equity ${ }^{(2)}$ |  | 5,552,291 |  | 5,358,155 |  | 5,103,144 |
| Total liabilities and stockholders' equity | \$ | 9,750,421 | \$ | 9,594,431 | \$ | 9,364,648 |

(1) Derived from audited financial statements
(2) Common shares issued and outstanding were 158,568 as of December $27,2015,158,101$ as of September 27,2015 , and 158,531 as of June 28,2015

## LAM RESEARCH CORPORATION

## CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

| Three Months Ended |  | Six Months Ended |  |
| :--- | :--- | :--- | :--- | :--- |
| December 27, | September 27, | December 28, | December 27, |
| 2015 | 2015 | 2014 | 2015 |
|  |  |  |  |
| (unaudited) |  |  |  |

CASH FLOWS
FROM
OPERATING
ACTIVITIES:

| Depreciation and amortization | 71,798 |  | 70,590 |  | 69,536 |  | 142,388 | 1 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Deferred income taxes | 8,176 |  | (5,563 | ) | 3,320 |  | 2,613 | 6 |
| Equity-based compensation expense | 32,570 |  | 35,774 |  | 30,632 |  | 68,344 | 6 |
| Income tax benefit on equity-based compensation plans | 2,168 |  | 3,545 |  | 1,141 |  | 5,713 | 1 |
| Excess tax benefit on equity-based compensation plans | (2,181 | ) | (3,572 | ) | (599 | ) | (5,753 | ( |
| Amortization of note discounts and issuance costs | 23,649 |  | 9,831 |  | 9,199 |  | 33,480 | 1 |
| Gain on sale of business | - |  | - |  | - |  | - | ( |
| Other, net | 10,592 |  | 10,011 |  | 1,607 |  | 20,603 | 7 |
| Changes in operating assets and liabilities | (75,207 | ) | 39,702 |  | (130,537 | ) | (35,505 | ( |
| Net cash provided by operating activities | 294,545 |  | 448,997 |  | 161,239 |  | 743,542 | 3 |

CASH FLOWS
FROM
INVESTING
ACTIVITIES:

| Capital expenditures and intangible | (28,143 | ) | (49,454 | ) | (61,363 | ) | (77,597 | ) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |

Business
acquisitions,
net of cash
acquired

| Net sale (purchase) of available-forsale securities | 39,202 |  | (28,203 | ) | (321,590 | ) | 10,999 |  | (\% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Repayment of notes receivable | 8,082 |  | - |  | 3,978 |  | 8,082 |  | 3 |
| Proceeds from sale of business | - |  | - |  | - |  | - |  | 4 |
| Other, net | $(4,746$ | ) | (1,500 | ) | 100 |  | (6,246 | ) | 1 |
| Net cash provided by (used for) investing activities | 14,395 |  | (79,157 | ) | (378,875 | ) | (64,762 | ) | ( |

CASH FLOWS
FROM
FINANCING
ACTIVITIES:

Principal
payments on
long-term
debt and
capital lease
obligations
and payments
for debt
issuance costs

Excess tax
benefit on
equity-based
compensation
plans

| Treasury stock purchases |  | (12,798 | ) |  | (98,385 | ) |  | (65,536 | ) |  | (111,183 | ) |  | (: |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Dividends paid |  | (47,896 | ) |  | (47,659 | ) |  | (29,381 | ) |  | (95,555 | ) |  | (! |
| Re-issuance of treasury stock related to employee stock purchase plan |  | - |  |  | 19,245 |  |  | - |  |  | 19,245 |  |  | 1 |
| Proceeds from issuance of common stock |  | 1,173 |  |  | 377 |  |  | 4,223 |  |  | 1,550 |  |  | 8 |
| Other, net |  | (22 | ) |  | (300 | ) |  | - |  |  | (322 | ) |  | - |
| Net cash used for financing activities |  | (85,736 | ) |  | (123,246 | ) |  | (90,769 | ) |  | (208,982 | ) |  | (: |
| Effect of exchange rate changes on cash and cash equivalents |  | 344 |  |  | (3,808 | ) |  | (3,998 | ) |  | (3,464 | ) |  | $(1$ |
| Net increase (decrease) in cash and cash equivalents |  | 223,548 |  |  | 242,786 |  |  | (312,403 | ) |  | 466,334 |  |  | ( |
| Cash and cash equivalents at beginning of period |  | 1,744,325 |  |  | 1,501,539 |  |  | 1,293,678 |  |  | 1,501,539 |  |  | 1 |
| Cash and cash equivalents at end of period | \$ | 1,967,873 |  | \$ | 1,744,325 |  | \$ | 981,275 |  | \$ | 1,967,873 |  | \$ | 9 |

## Non-GAAP Financial Summary

(in thousands, except percentages and per share data)
(unaudited)

|  | Three Months Ended |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | December 27, |  |  | September 27, |  |  |
|  | 2015 |  |  | 2015 |  |  |
| Revenue | \$ | 1,425,534 |  | \$ | 1,600,043 |  |
| Gross margin | \$ | 648,409 |  | \$ | 743,984 |  |
| Gross margin as percentage of revenue |  | 45.5 | \% |  | 46.5 | \% |
| Operating expenses | \$ | 352,135 |  | \$ | 363,596 |  |
| Operating income | \$ | 296,274 |  | \$ | 380,388 |  |
| Operating margin as a percentage of revenue |  | 20.8 | \% |  | 23.8 | \% |
| Net income | \$ | 270,313 |  | \$ | 313,045 |  |
| Net income per diluted share | \$ | 1.57 |  | \$ | 1.82 |  |
| Shares used in per share calculation - diluted |  | 171,796 |  |  | 172,046 |  |

Reconciliation of U.S. GAAP Net Income to Non-GAAP Net Income and U.S. GAAP number of dilutive shares to Non-GAAP number of dilutive shares
(in thousands, except per share data)

```
(unaudited)
```

|  | Three Months Ended |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | December 27, |  |  | September 27, |  |  | June 28, |  |  | March 29, |  |  |
|  | 20 |  |  |  |  |  |  |  |  |  |  |  |
| U.S. GAAP net income | \$ | 222,980 |  | \$ | 288,679 |  |  | 131,271 |  |  | 206,285 |  |
| Pre-tax non-GAAP items: |  |  |  |  |  |  |  |  |  |  |  |  |
| Amortization related to intangible assets acquired in Novellus transaction - cost of goods sold |  | 21,250 |  |  | 21,250 |  |  | 21,286 |  |  | 21,286 |  |
| Acquisition-related inventory fair value impact - cost of goods sold |  | 649 |  |  | - |  |  | 1,192 |  |  | 308 |  |
| Impairment of long lived asset - cost of goods sold |  | - |  |  | - |  |  | 9,821 |  |  | - |  |
| Restructuring charges cost of goods sold |  | - |  |  | 371 |  |  | - |  |  | - |  |
| Restructuring charges research and development |  | 34 |  |  | 4,206 |  |  | - |  |  | - |  |
| Acquisition costs selling, general and administrative |  | 17,392 |  |  | - |  |  | - |  |  | - |  |
| Amortization related to    <br> intangible assets    <br> acquired in Novellus 16,083 16,083 16,083 <br> transaction - selling,    <br> general and  16,083  <br> administrative    |  |  |  |  |  |  |  |  |  |  |  |  |
| Restructuring charges selling, general and administrative |  | 2,032 |  |  | 3,050 |  |  | 434 |  |  | (495 | ) |
| Goodwill impairment selling, general and administrative |  | - |  |  | - |  |  | 79,444 |  |  | - |  |
| Amortization of note discounts - other expense, net |  | 9,258 |  |  | 9,122 |  |  | 9,019 |  |  | 8,749 |  |
| Amortization of bridge Ioan issuance costs other expense, net |  | 13,573 |  |  | - |  |  | - |  |  | - |  |
| Net income tax benefit on non-GAAP items |  | (19,335 | ) |  | (7,791 | ) |  | (9,605 | ) |  | (7,181 | ) |
| Cumulative income tax benefit due to a court ruling |  | - |  |  | (21,925 | ) |  | - |  |  | - |  |
| Income tax expense (benefit) on resolution or additional accrual for certain tax matters |  | - |  |  | - |  |  | 1,078 |  |  | (124 | ) |
| Income tax benefit from tax extenders, primarily the research and development credit |  | (13,603 | ) |  | - |  |  | - |  |  | - |  |
| Non-GAAP net income | \$ | 270,313 |  | \$ | 313,045 |  | \$ | 260,023 |  | \$ | 244,911 |  |
| Non-GAAP net income per diluted share | \$ | 1.57 |  | \$ | 1.82 |  | \$ | 1.50 |  | \$ | 1.40 |  |
| U.S. GAAP number of shares used for per diluted share calculation |  | 174,242 |  |  | 174,374 |  |  | 176,575 |  |  | 177,531 |  |
| Effect of convertible note hedge |  | (2,446 | ) |  | (2,328 | ) |  | (2,934 | ) |  | (3,060 | ) |
| Non-GAAP number of shares used for per diluted share calculation |  | 171,796 |  |  | 172,046 |  |  | 173,641 |  |  | 174,471 |  |

## Reconciliation of U.S. GAAP Gross Margin, Operating Expenses and Operating Income to Non-GAAP Gross Margin, Operating Expenses and Operating Income

## (unaudited)

| Three Months Ended |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | December 27, |  |  | September 27, |  |  |
|  | 2015 |  |  | 2015 |  |  |
| U.S. GAAP gross margin | \$ | 626,510 |  | \$ | 722,363 |  |
| Pre-tax non-GAAP items: |  |  |  |  |  |  |
| Amortization related to intangible assets acquired in Novellus transaction - cost of goods sold |  | 21,250 |  |  | 21,250 |  |
| Acquisition-related inventory fair value impact - cost of goods sold |  | 649 |  |  | - |  |
| Restructuring charges - cost of goods sold |  | - |  |  | 371 |  |
| Non-GAAP gross margin | \$ | 648,409 |  | \$ | 743,984 |  |
| U.S. GAAP gross margin as a percentage of revenue |  | 43.9 | \% |  | 45.1 | \% |
| Non-GAAP gross margin as a percentage of revenue |  | 45.5 | \% |  | 46.5 | \% |
| U.S. GAAP operating expenses | \$ | 387,676 |  | \$ | 386,935 |  |
| Pre-tax non-GAAP items: |  |  |  |  |  |  |
| Restructuring charges - research and development |  | (34 | ) |  | (4,206 | ) |
| Acquisition costs - selling, general and administrative |  | (17,392 | ) |  | - |  |
| Amortization related to intangible assets acquired in Novellus transaction - selling, general and administrative |  | (16,083 | ) |  | (16,083 | ) |
| Restructuring charges - selling, general and administrative |  | (2,032 | ) |  | (3,050 | ) |
| Non-GAAP operating expenses | \$ | 352,135 |  | \$ | 363,596 |  |
| Non-GAAP operating income | \$ | 296,274 |  | \$ | 380,388 |  |
| GAAP operating margin as percent of revenue |  | 16.8 | \% |  | 21.0 | \% |
| Non-GAAP operating margin as a percent of revenue |  | 20.8 | \% |  | 23.8 | \% |

[^0]
## News Provided by Acquire Media


[^0]:    Lam Research Corporation Contacts:
    Satya Kumar
    Investor Relations
    phone: 510-572-3232
    e-mail: satya.kumar@lamresearch.com
    Source: Lam Research Corporation

